Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

It’s just so often that we are seeing patients that are presenting at advanced stages, where chances for a cure are very slim ...

Lung Cancer Test Predicts Survival in Early Stages ... Experimental mRNA Cancer Vaccine Shows Potential for Advanced Stage Cancer Patients in Phase 1 Trial Sep. 13, 2024 — Interim data from ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

Hillcrest Medical Center displayed new advanced technology in a thoracic oncology mobile experience aimed at educating patients on the advancements made in diagnosing and treating lung cancer.

A key lung cancer congress held in Europe disclosed that a new breakthrough has been made by Hengrui Pharmaceuticals, a leading innovator in China’s pharmaceutical sector, to help prolong and improve ...

Survival rates for metastatic lung cancer Researchers base cancer survival rates on the type of cancer, the subtype of cancer, and the stage at diagnosis. When considering the 5-year survival rate ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

Researchers evaluated billing for early palliative care among Medicare beneficiaries who were newly diagnosed with 1 of 6 common distant-stage cancers.

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...